<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DROPERIDOL</span><br/>(droe-per'i-dole)<br/><span class="topboxtradename">Inapsine<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">butyrophenone</span>; <span class="classification">antiemetic</span><br/><b>Prototype: </b>Haloperidol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Butyrophenone derivative structurally and pharmacologically related to haloperidol. Antagonizes emetic effects of morphine-like
         analgesics and other drugs that act on chemoreceptor trigger zone. Mild alpha-adrenergic blocking activity and direct vasodilator
         effect may cause hypotension. Acts primarily at subcortical level to produce sedation.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Sedative property reduces anxiety and motor activity without necessarily inducing sleep; patient remains responsive. Potentiates
         other CNS depressants. Also has antiemetic properties.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To produce tranquilizing effect and to reduce nausea and vomiting during surgical and diagnostic procedures. Also for premedication,
         during induction, and as adjunct in maintenance of general or regional anesthesia. Principally used in fixed combination with
         the potent narcotic analgesic fentanyl (Innovar) to produce neuroleptanalgesia (quiescence, reduced motor activity, and indifference
         to pain and environmental stimuli) to permit carrying out a variety of diagnostic and minor surgical procedures.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>IV antiemetic in cancer chemotherapy.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known intolerance to droperidol. Safe use during pregnancy (category C), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Older adult, debilitated, and other poor-risk patients; Parkinson's disease; hypotension; liver, kidney, cardiac disease;
         cardiac bradyarrhythmias.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Premedication</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 2.510 mg 3060 min preoperatively<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> <i>212 y</i>, 0.0880.165 mg/kg 3060 min preoperatively<br/><br/><span class="indicationtitle">Maintenance of General Anesthesia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> <i>Induction</i>, 0.220.275 mg/kg; <i>Maintenance</i>, 1.252.5 mg<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> <i>212 y</i>, 0.0880.165 mg/kg<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give deep IM into a large muscle.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV administration to infants and children: Verify correct rate of IV injection with physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate of 10 mg or fraction thereof over 3060 s.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span> <b> Fluorouracil,</b> <b>furosemide,</b> <b>heparin,</b> <b>leucovorin,</b> <b>methotrexate,</b> <b>pentobarbital.</b> <span class="incompattype">Y-site:</span> <b>Fluorouracil,</b> <b>furosemide,</b> <b>heparin,</b> <b>leucovorin,</b> <b>methotrexate,</b> <b>nafcillin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F), unless otherwise directed by manufacturer. Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Postoperative drowsiness, extrapyramidal symptoms:</span> dystonia, akathisia, oculogyric crisis; dizziness, restlessness, anxiety, hallucinations, mental depression. <span class="typehead">CV:</span> <span class="speceff-common">Hypotension, tachycardia,</span> irregular heartbeats <span class="speceff-common">(prolonged QTc interval even at low doses)</span>. <span class="typehead">Other:</span> Chills, shivering, <span class="speceff-life">laryngospasm, bronchospasm</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 310 min. <span class="typehead">Peak:</span> 30 min. <span class="typehead">Duration:</span> 24 h; may persist up to 12 h. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine and feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor ECG throughout therapy. Report immediately prolongation of QTc interval.</li>
<li>Monitor vital signs closely. Hypotension and tachycardia are common adverse effects.</li>
<li>Exercise care in moving medicated patients because of possibility of severe orthostatic hypotension. Avoid abrupt changes
            in position.
         </li>
<li>Observe patients for signs of impending respiratory depression carefully when receiving a concurrent narcotic analgesic carefully.</li>
<li> 								Note: EEG patterns are slow to return to normal during the postoperative period. 							</li>
<li>Observe carefully and report promptly to physician early signs of acute dystonia: Facial grimacing, restlessness, tremors,
            torticollis, oculogyric crisis. Extrapyramidal symptoms may occur within 2448 h postoperatively.
         </li>
<li> 								Note: Droperidol may aggravate symptoms of acute depression. 							</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>